Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck.

The article comments on a paper by A. R. Parikh and colleagues on the effectiveness and safety of cetuximab dosage in patients with colorectal, head and neck cancer. Topics mentioned include the comparison of weekly and biweekly dosage of cetuximab in patients with metastatic colororectal and squamous cell carcinoma of the head and neck cancer, the cost-effectiveness of biweekly dosing to reduce hospital visits and infusion times, and the improvement in patients' quality of life.